![Shahed Badiyan Profile](https://pbs.twimg.com/profile_images/1783529534186221574/YzJyoUtw_x96.jpg)
Shahed Badiyan
@BadiyanMD
Followers
148
Following
453
Statuses
74
Radiation Oncologist, Director of Clinical Adaptive Therapy @UTSW
Dallas, TX
Joined April 2024
RT @BobTimmermanMD: Great visit to the Normandy Hadron Facility in Caen, France along with Dr. Habrand’s team and IBA executives, including…
0
17
0
@jryckman3 @5_utr I would assume they removed it because ARTDECO included cervical esophagus patients and was a negative trial, though the number of cervical patients was of course low.
1
0
3
@DoctorCliffyy @HardenedBeam @DrewMoghanaki I'd argue it is the RFA that is actually accomplishing something. The TACE is just adding cost.
1
0
1
@DoctorCliffyy @HardenedBeam @DrewMoghanaki If you read the paper you will see that few patients received more than 268 Gy and those that did had tumors on the smaller side which is consistent with Legacy data. The problem is large tumors >5 cm.
2
0
1
@DoctorCliffyy @HardenedBeam @DrewMoghanaki Y90 dose distribution is fine for small tumors, but larger tumors end up with cold spots resulting in inadequate local tumor control. In our analysis of pts getting dose-escalated Y90 for primary liver cancers we found that freedom from local progression at 1 year was only 54%.
1
0
1
@DoctorCliffyy @nbn426 @DrewMoghanaki @ldawsonmd @NiuSanford Every time I've wanted to do a Y90 vs SBRT randomized trial it has been my IR colleagues that have refused. The vast majority of pts receiving SBRT don't receive proton therapy, they receive photons. The Loma Linda Protons vs TACE randomized trial showed 28% cost savings w/ PBT.
1
0
2
@jryckman3 @drjamesgood @OncoThor @TheRealDoctorOs @5_utr Another big challenge with interpreting the results of TARE studies is the fact that they never report local control. They only report radiographic response which is a clinically meaningless endpoint for a local therapy.
2
0
10
@DoctorCliffyy @DrewMoghanaki Limitations of SBRT? Please point me to the randomized trials showing benefit of Y90.
0
0
2
Very excited to participate!
Our featured speakers for the #ACRO2025 Thoracic session are Drs. Shahed Badiyan, Andrea Wolf, and Jing Zeng! Join us for "Redefining Best Practices in Locally Advanced #LungCancer" by registering at today!
0
1
9
RT @NiuSanford: We also consider SBRT for oligoprogression in HCC b/c: -high local control -usually low toxicity -allows pt to stay on 1st…
0
19
0
@NiuSanford Yeah if you look at the graph the cumulative incidence of local failure after TACE alone approached 90% so it’s like sprinkling fairy dust on the liver. At least the radiation accomplished something.
1
0
12
RT @ArndtVogel: Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma ≤5 cm @JCO_ASCO htt…
0
46
0
RT @UTSW_RadOnc: (1/2) Led by Drs. @ndesai2005 and @BinCaiMedPhys, our department imaged our first patient on the Reflexion PET-linac platf…
0
15
0
RT @NiuSanford: First clinical PULSAR study is out! Congrats @MDohopolski, @TuDDan, @BobTimmermanMD & rest of UTSW CNS team! https://t.c…
0
29
0
RT @PTCOGNA: We are less than week away from the PTCOG-NA 10th Annual Meeting in New York City! Looking forward to an amazing program! http…
0
1
0
RT @PTCOGNA: We are two weeks away from the PTCOG-NA 10th Annual Meeting in New York City. We are looking forward to seeing you there! Regi…
0
3
0
RT @NiuSanford: Not surprised rad onc applicant # is up. It's a great specialty & job market has been good. Look forward to meeting our @U…
0
10
0
RT @PTCOGNA: We are 3 weeks away from the PTCOG-NA 10th Annual Meeting in New York City! Rooms at the New York Hilton Midtown and Le Meridi…
0
2
0
RT @PTCOG_Official: Submit your research on Clinics for #PTCOG63! 🚀 Share your insights on #ParticleTherapy, from novel treatment strategie…
0
3
0